OWC Pharmaceutical has completed the pre-clinical development of its next generation, orally-disintegrating tablet containing cannabis extract with specific amounts of the cannabinoids tetrahydrocannabinol ("THC") and cannabidiol ("CBD"). The tablet is targeted at different indications and will be available in various ratios of THC to CBD and various doses of these actives.